It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals ...

Conditions are getting a bit more challenging for the drugmaker.

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

CHICAGO, Oct 29 (Reuters) - Starting on a more gradual dosing schedule of Eli Lilly's (LLY.N), opens new tab Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks to buy before they split next. There’s been a notable sense of fear among investors ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

Eli Lilly and Company Stock Down 1.3 % Eli Lilly and Company stock opened at $891.66 on Friday. The firm has a market cap of $847.44 billion, a P/E ratio of 131.32, a P/E/G ratio of 2.79 and a ...